Andy/iStock via Getty Images
Beam Therapeutics (BEAM) lost more than 10% on Tuesday after announcing updated data from a Phase 1/2 trial for BEAM-302, its gene-editing therapy for a genetic disorder called alpha-1 antitrypsin deficiency.
Citing a June 24 data cut, the Cambridge, Massachusetts-based biotech said